Gilead Sciences (GILD) 10-Q2024 Q1 Quarterly report

Filed: 8 May 24, 4:58pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: addressable, adjudicate, agonist, anniversary, appellate, arrive, biliary, BIOSECURE, boxed, Bulk, bulveritide, carbon, children, conclusion, CymaBay, deliver, domvanalimab, dosage, duration, electricity, essential, exploitation, explored, expressed, Florida, fund, gathering, hematologic, incentivize, incident, jurisdiction, jurisdictional, kg, landscape, liable, lung, media, metabolic, modern, newly, NSCLC, older, Oregon, Orphan, outweigh, PDAB, pediatric, peroxisome, PPAR, preclude, preclusion, preferred, pregnant, priority, prohibit, prolonged, quickly, recover, regimen, reinforcing, remanded, repatriation, restructuring, sacituzumab, sea, secondary, seladelpar, SG, sheet, shown, smaller, SOFR, speed, suppressed, Supreme, suspected, switching, temporary, trispecific, tumor, unaffordable, unvested, viability, voluntarily, voting, warning, weather, weigh, workforce, writ, Xilio, zimberelimab

Removed: adjusting, aggregate, allocated, AmerisourceBergen, automated, bictegravir, bioanalytical, biology, biotech, broader, Cabaret, carry, Chapter, Code, combine, competitively, Custodial, derived, determinable, disaggregation, Dr, embedded, Emory, endocrine, enhance, Eshhar, EVG, extend, Extension, fall, flat, formatted, Frederick, generated, handling, individually, Inline, instance, Interactive, Japan, kinase, lifted, Linkbase, Master, meeting, Merger, merit, molecule, myeloma, Oceanside, Page, pathway, payable, percent, preliminary, principal, produce, profit, readily, reclassification, relationship, remained, repeat, Reserve, retroviral, Schema, SEC, setting, split, stemming, systemic, Taxonomy, Title, Tobacco, Trustee, UC, understand, unobservable, unresectable, updated, XBRL, Zelig

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated GILD transcripts

GILD similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATIONS

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350, as adopted), Daniel P. O’Day, the Chairman and Chief Executive Officer of Gilead Sciences, Inc. (the Company), and Andrew D. Dickinson, the Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

1. The Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the Report) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 8, 2024


/s/ DANIEL P. O’DAY						/s/ ANDREW D. DICKINSON
Daniel P. O’Day Chairman and Chief Executive Officer						Andrew D. Dickinson Chief Financial Officer

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.